A case series analysis on the clinical experience of Impella 5.5 ® at a large tertiary care centre

ConclusionsIn this early experience of the pVAD 5.5, procedural and device-related complications were observed but were manageable, and overall survival was high in this critically ill cohort, particularly when the device was used as a bridge to other therapies.

Source: ESC Heart Failure - August 17, 2021 Category: Cardiology Authors: Peter J. Kennel, Heidi Lumish, Yuji Kaku, Justin Fried, Ajay J. Kirtane, Dimitri Karmpaliotis, Hiroo Takayama, Yoshifumi Naka, Gabriel Sayer, Nir Uriel, Koji Takeda, Amirali Masoumi Tags: Original Research Article Source Type: research